{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-21-014000","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.849839+00:00","generated_at":"2026-06-28T14:55:41.621636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GlycoMimetics Q3 cash $101.9M; uproleselan Phase 3 enrollment nearing completion","bullets":["Cash and cash equivalents $101.9M at Sept 30, 2021, down from $137.0M at Dec 31, 2020.","R&D expenses increased to $13.3M from $10.7M YoY, driven by Phase 3 trial costs.","Phase 3 trial of uproleselan in relapsed/refractory AML nearing enrollment completion; top line data after 2022.","Data published in BLOOD showed 69% MRD negative rate in evaluable relapsed/refractory AML patients.","New CEO Harout Semerjian appointed effective August 6, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-21-014000","json":"https://secwatch.observer/filing/0001558370-21-014000.json","markdown":"https://secwatch.observer/filing/0001558370-21-014000.md","text":"https://secwatch.observer/filing/0001558370-21-014000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/0001558370-21-014000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837021014000/glyc-20211102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:55:41.621636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}